Nuvalent (NUVL) Net Income towards Common Stockholders (2020 - 2026)

Nuvalent's (NUVL) quarterly Net Income towards Common Stockholders came in at -$109.3 million in Q1 2026, down 29.2% YoY from -$154.3 million in Q1 2025, and down 277.94% on a QoQ basis from -$28.9 million in Q4 2025.

Nuvalent (NUVL) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Nuvalent (NUVL) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$109.3 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 29.2% year-over-year to -$109.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$360.3 million (down 19.75% YoY) and the FY2025 annual result came in at -$335.6 million, down 28.7% from the prior year.
  • Net Income towards Common Stockholders eased to -$109.3 million in Q1 2026, from -$28.9 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$18.6 million in Q1 2022 to a low of -$122.4 million in Q3 2025.
  • A 5-year average of -$54.0 million and a median of -$38.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 201.38% — and 2025, when it soared 61.33%.
  • Tracing NUVL's Net Income towards Common Stockholders over 5 years: stood at -$27.5 million in 2022, then sank by 39.44% to -$38.3 million in 2023, then sank by 95.24% to -$74.8 million in 2024, then soared by 61.33% to -$28.9 million in 2025, then slumped by 277.94% to -$109.3 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$109.3 million (Q1 2026), -$28.9 million (Q4 2025), and -$122.4 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 472.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - -644.37 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 237.01 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 930.12
7 Royalty Pharma 33.72 Bn 35.84 Bn - 81.49 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 164.49 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -13.27 Mn
10 Nuvalent 9.10 Bn 9.10 Bn - -109.28 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -109.28 Mn
Dec 31, 2025 -28.91 Mn
Sep 30, 2025 -122.44 Mn
Jun 30, 2025 -99.65 Mn
Mar 31, 2025 -84.58 Mn
Dec 31, 2024 -74.76 Mn
Sep 30, 2024 -84.35 Mn
Jun 30, 2024 -57.17 Mn
Mar 31, 2024 -44.48 Mn
Dec 31, 2023 -38.29 Mn
Sep 30, 2023 -33.65 Mn
Jun 30, 2023 -29.09 Mn
Mar 31, 2023 -25.19 Mn
Dec 31, 2022 -27.46 Mn
Sep 30, 2022 -20.58 Mn
Jun 30, 2022 -19.60 Mn
Mar 31, 2022 -18.57 Mn
Dec 31, 2021 -40.78 Mn
Sep 30, 2021 -12.43 Mn
Jun 30, 2021 -9.85 Mn